Retrospective evaluation of neurotoxic rattlesnake envenomation in dogs and cats: 34 cases (2005-2010)
Research article published in Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001) (2012)
Abstract
OBJECTIVE: To describe common physical examination findings, clinicopathologic changes, treatment, and outcome in patients with evidence of neurotoxicity secondary to rattlesnake envenomation. DESIGN: Retrospective multicenter study (2005-2010). SETTING: Three private veterinary referral centers. ANIMALS: Thirty-four client-owned cats and dogs with evidence of neurotoxicity secondary to rattlesnake envenomation. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Patient signalment, approximate time between envenomation and presentation for veterinary evaluation, physical examination and clinicopathologic findings, treatments, serial neurologic assessment, duration of hospitalization, and outcome were recorded. Signs of neurotoxicity such as ataxia, postural deficits, muscle fasciculations, paresis, paralysis, or seizures were required for inclusion into the study. The incidence of neurotoxicity amongst the general population treated with antivenin for rattlesnake envenomation in this study was 5.4%. Crotalidae Polyvalent Immune Fab(b) and veterinary approved Antivenin (Crotalidae) Polyvalent(a) were both used in this study. There was no statistically significant difference between type of antivenin or number of vials of antivenin administered and neurologic status, length of hospitalization (LOH), or survival. Hypokalemia was a frequently identified complication, but the presence of hypokalemia did not have a statistically significant association with LOH or survival. Four of the 34 patients (11.8%) required positive pressure ventilation for signs consistent with respiratory paralysis; 2 of these patients survived to discharge. Overall mortality rate was 17.6%. Survival was not significantly different between dogs and cats. However, cats had a significantly longer LOH when compared with dogs (median LOH 3.5 d for cats, 2 d for dogs). Cats appear to be overrepresented in the subset of envenomated patients with neurotoxicity. CONCLUSION: Although the incidence of neurotoxicity secondary to rattlesnake envenomation may be relatively low, patients can have rapid progression of their clinical signs and a higher mortality rate, necessitating timely and appropriate treatment. Patients treated for neurotoxicity secondary to envenomation appear to have a fair to good prognosis.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
To describe common physical examination findings, clinicopathologic changes, treatment, and outcome in patients with evidence of neurotoxicity secondary to rattlesnake envenomation.
Warum dies für die Hirudotherapie relevant ist
Diese retrospektive multizentrische veterinärmedizinische Studie beschrieb Befunde der klinischen Untersuchung, klinisch-pathologische Veränderungen, Behandlung und Outcome bei 34 Katzen und Hunden mit Neurotoxizität infolge einer Klapperschlangen-Vergiftung, die zwischen 2005 und 2010 in drei privaten Überweisungszentren behandelt wurden. Sie berichtet über neurotoxische Zeichen (Ataxie, Parese, Paralyse, Krampfanfälle), eine Mortalitätsrate von 17,6 % sowie Vergleiche zwischen Antivenin-Typen, ohne Erwähnung von Egeln, Hirudotherapie, Hirudin oder des Egel-Sekretoms. Obwohl das Thema Vergiftung – ein Konzept, das oberflächlich mit der therapeutischen Verwendung von aus Speichel stammenden bioaktiven Verbindungen verwandt ist – betroffen ist, sind die Organismen, das Gift und der klinische Kontext vollständig unabhängig von Egeln. Es besteht keine vertretbare Relevanz für den Bereich der ASH; dies ist eine veterinärtoxikologische Studie.
Zitation
Retrospective evaluation of neurotoxic rattlesnake envenomation in dogs and cats: 34 cases (2005-2010)
Julius TM et al. · Journal of veterinary emergency and critical care (San Antonio, Tex. : 2001), 2012
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 27, 2026 · Letzte Aktualisierung der Website: 18. Juni 2026